Semaglutide in India 2026: What Patent Expiry Means for Price and Access
India's semaglutide patent expired March 20, 2026. Within 48 hours, 15 generic versions launched at ₹1,290/month — a 90% drop from Ozempic. Here's what it means for Indian patients.
On March 20, 2026, Novo Nordisk's Indian patent on semaglutide — the active ingredient in Ozempic, Wegovy, and Rybelsus — officially expired. Within 48 hours, the first generic versions were on pharmacy shelves. Within three weeks, 15 different Indian manufacturers had launched authorised generic semaglutide products at prices as low as ₹1,290 per month, representing a 90% reduction from the branded Ozempic price.
If you are an Indian patient who has been considering GLP-1 weight management therapy — or who has been priced out of it until now — this is the most important development in the category in your lifetime. This article explains what happened, why it matters, which manufacturers are involved, and what you should know before choosing a generic.
Before the patent expiry: the Indian semaglutide market
Until March 20, 2026, Indian patients who wanted semaglutide had essentially three options:
At these prices, semaglutide was accessible only to a narrow slice of the urban upper-middle class — roughly the same slice of the population that could absorb a ₹10,000–15,000 monthly medication expense on top of existing healthcare costs. The overall Indian weight-loss medication market was estimated at ₹1,400 crore (approximately €150 million) in 2025, and growing fast — but bottlenecked by the price.
Meanwhile, obesity and overweight prevalence in urban India was rising sharply. According to the National Family Health Survey (NFHS-5), the proportion of Indian adults classified as overweight or obese roughly doubled between 2005 and 2021, with urban populations showing the fastest growth. Demand for effective weight management was enormous. Supply, at affordable prices, was almost non-existent.
What happened on and after March 20, 2026
The patent expiry had been anticipated by Indian generic manufacturers for years. Several had been running parallel research and development programmes specifically timed for launch on day one. A Delhi High Court ruling in March 2026 confirmed that Dr Reddy's Laboratories had the legal right to manufacture and export semaglutide API (the raw active ingredient) — a ruling that effectively unlocked generic production across the Indian industry.
Within 48 hours of the March 20 expiry date, the first generic products were being sold by pharmacies. Within three weeks, the following manufacturers had authorised generic semaglutide on the market in India:
All of these companies hold valid manufacturing licences from the Central Drugs Standard Control Organisation (CDSCO), India's national drug regulator. All of their products underwent bioequivalence testing and CDSCO review before launch. They are, in every sense that matters to a patient, the same medicine as Ozempic — made by different companies, under different names, at very different prices.
The cheapest authorised generic on the market is now approximately ₹1,290 per month for the starting dose, with maintenance dose generics available in the ₹2,500–4,000 per month range depending on manufacturer and pharmacy. Compare this to the branded Wegovy price of ₹16,400 per month — a 92% reduction.
What patients should know before choosing a generic
With 15+ generics available, Indian patients now have genuine choice. Here's what to evaluate:
1. Verify the CDSCO approval
Every legitimate generic semaglutide product sold in India has a CDSCO reference number printed on the packaging. You can ask your pharmacy or doctor to show it to you, and you can cross-check it against the public CDSCO database. This takes 30 seconds and is the single most important verification step.
Products sold online without a CDSCO reference — especially through WhatsApp groups, Instagram DMs, or unbranded websites — should be assumed to be grey market until proven otherwise. The grey market exists in India as in every other country, and the high demand for semaglutide has attracted counterfeiters. A dramatic discount below the ₹1,290 floor price is a red flag, not a deal.
2. Understand the form factor
Generic semaglutide in India is available in multiple forms:
Your doctor will recommend the form most appropriate for your situation. Don't self-select based on price alone — the pen has meaningful advantages in dose accuracy, especially during the initial titration weeks when precision matters.
3. Ask about the specific manufacturer
It's a fair question to ask your doctor or pharmacy: which manufacturer's product will you be dispensing, and why that one? Legitimate pharmacies will answer without hesitation. Some patients prefer to stick with the larger, better-known manufacturers (Sun Pharma, Dr Reddy's, Cipla) for brand familiarity — that's a reasonable preference. Others will go with whatever is cheapest and in stock, which is also reasonable if CDSCO approval is confirmed.
None of the CDSCO-approved products is meaningfully "better" than another in any way a patient can perceive — they all contain the same molecule, at the same strength, manufactured to the same regulatory standards. The differences are in packaging, pen design, and price.
4. Confirm the cold chain
Semaglutide is a peptide. It must be kept between 2°C and 8°C from the moment it leaves the manufacturer's facility until it reaches your refrigerator. This is the single most common failure point in the Indian supply chain — and it's one of the main reasons people should choose pharmacies carefully rather than buying from random online sources.
Questions to ask your pharmacy:
Unfortunately, not every major Indian online pharmacy handles cold chain well. Independent reporting in 2025 and 2026 has highlighted inconsistent cold chain practices at several high-volume pharma marketplaces, where refrigerated products are sometimes shipped without adequate temperature protection. This is a real risk to you, because a semaglutide product that has been warm for several days may have lost a significant portion of its potency. You would not be able to tell from the packaging.
5. Work with a licensed doctor, not a questionnaire
Even at ₹1,290 per month, semaglutide is not a medication you should start without a real medical consultation. A licensed doctor needs to assess your BMI, medical history, existing medications, and specific goals before deciding whether semaglutide is appropriate for you. A doctor should also plan your titration schedule, set expectations for side effects, and create a follow-up plan.
Many online platforms — in India and elsewhere — try to shortcut this with an automated questionnaire that produces a prescription without a real doctor ever seeing your case. This is not a substitute for a medical consultation, and in many cases it's a legal shortcut that avoids proper physician oversight. Insist on speaking with a licensed doctor, in person or by video, before starting treatment. Any platform that resists this is not one you want to work with.
The practical reality: is ₹1,290 really what you'll pay?
Almost, but not exactly. The ₹1,290 figure is the wholesale manufacturer price for the cheapest starting-dose generic. The actual monthly cost you'll pay includes:
Realistic total monthly cost for a properly supervised generic semaglutide programme in India in 2026: ₹2,500 to ₹6,000. Still roughly 70–85% less than the branded equivalent, and now within reach for a much larger segment of the Indian population than ever before.
What this means for Indian healthcare more broadly
The generic semaglutide moment in India is important for reasons beyond any single patient's experience:
Where Magistra comes in
We believe every Indian patient who qualifies for GLP-1 weight management therapy should have access to authentic, CDSCO-approved generic semaglutide, dispensed by a licensed doctor and a licensed pharmacy, delivered with proper cold chain, at a price that reflects the real cost of the medicine.
That's what we're building. We're launching in India in 2026 and we'd love to have you with us from day one. Join our waitlist and we'll let you know when we go live in your city — Bangalore, Mumbai, Delhi NCR, Pune, Hyderabad, and Chennai first, with more cities following through the year.
This article is educational and not a substitute for medical advice. Semaglutide is a prescription medication and should only be used under the supervision of a licensed healthcare provider. All prices quoted are approximate as of April 2026 and vary between manufacturers, pharmacies, and locations.
Related reading:
Sources:
Klaar om te beginnen?
Vul een korte vragenlijst in en ontdek of een gepersonaliseerd programma bij je past.
Begin Nu